1. Home
  2. NEXA vs XERS Comparison

NEXA vs XERS Comparison

Compare NEXA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexa Resources S.A.

NEXA

Nexa Resources S.A.

HOLD

Current Price

$12.09

Market Cap

1.7B

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$10.81

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXA
XERS
Founded
1956
2005
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
NEXA
XERS
Price
$12.09
$10.81
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
★ $14.04
$12.86
AVG Volume (30 Days)
491.4K
★ 2.4M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 1.07%
N/A
EPS Growth
N/A
★ 100.00
EPS
★ N/A
N/A
Revenue
N/A
★ $49,590,000.00
Revenue This Year
$25.37
$32.91
Revenue Next Year
N/A
$23.75
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$5.05
$5.25
52 Week High
$16.89
$11.42

Technical Indicators

Market Signals
Indicator
NEXA
XERS
Relative Strength Index (RSI) 41.75 65.16
Support Level $11.79 $5.90
Resistance Level $14.98 N/A
Average True Range (ATR) 0.44 0.50
MACD 0.00 0.06
Stochastic Oscillator 7.43 76.05

Price Performance

Historical Comparison
NEXA
XERS

About NEXA Nexa Resources S.A.

Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: